Orenitram
Payments companies reported to CMS as associated with Orenitram. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Orenitram, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Orenitram
These are the largest totals companies reported as associated with Orenitram. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Harrison Farber | Boston, MA | Pulmonary Disease | $17,654.73 |
| Lana Melendres Groves | Albuquerque, NM | Pulmonary Disease | $16,493.60 |
| Stephen Chan | Pittsburgh, PA | Cardiovascular Disease | $13,716.90 |
| Mardi Gomberg-Maitland | Washington, DC | Cardiovascular Disease | $13,360.61 |
| Paul Forfia | Philadelphia, PA | Cardiovascular Disease | $12,437.93 |
| John Ryan | Salt Lake City, UT | Cardiovascular Disease | $12,006.22 |
| Imre Noth | Charlottesville, VA | Pulmonary Disease | $11,836.41 |
| Kenneth Mccurry | Cleveland, OH | Thoracic Surgery (Cardiothoracic Vascular Surgery) | $11,459.95 |
| Vinicio De Jesus Perez | Palo Alto, CA | Pulmonary Disease | $11,196.08 |
| Murali Chakinala | Saint Louis, MO | Pulmonary Disease | $10,128.03 |
Prescribed Orenitram?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.